Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma
Paul B. Chapman(Memorial Sloan Kettering Cancer Center), John M. Kirkwood(UPMC Hillman Cancer Center), Scott Saxman(Eastern Cooperative Oncology Group), Michael L. Meyers(Eastern Cooperative Oncology Group), Alicia N. Destro(Eastern Cooperative Oncology Group), Lawrence H. Einhorn(Eastern Cooperative Oncology Group), Sanjiv S. Agarwala(Goethe University Frankfurt), Colin B. Begg, Marc S. Ernstoff(Roswell Park Comprehensive Cancer Center), Katherine S. Panageas(Mayo Clinic), Alan N. Houghton(Eastern Cooperative Oncology Group), Lynn M. Schuchter(Eastern Cooperative Oncology Group)
Cited by 763
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
How To Build and Interpret a Nomogram for Cancer Prognosis
|Journal of Clinical Oncology|2008|3.4k